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We want to thank Dr. Pang et al. for their interest and important remarks regarding our 
article. In our recently published investigation we reported intra-platelet (IP) 5-
hydroxytryptamine (5-HT) levels to predict postoperative liver dysfunction and 
morbidity in patients undergoing liver resection. Based on its striking association with 
clinical outcome after partial hepatectomy, we thus proposed that IP 5-HT might 
represent a therapeutic target to accelerate liver regeneration after liver resection.1 It 
should be stressed that we did not evaluate the effects of IP 5-HT on tumor development 
or progression or its effects on viral hepatitis. Pang et al. point to a relevant issue with 
the potential use of 5-HT which may appear like a double-edge sword for the liver as it 
has also recently been discussed by Lesurtel et al. in more detail.2 We agree with Pang et 
al. that further research is required to determine whether perioperative modification of 
IP 5-HT levels is of overall benefit in patients undergoing liver resection and that the 
following aspects should be considered.  
First, adverse effects of 5-HT pointed out by Pang et al. have only been described in 
animal or cell culture experiments and need to be confirmed in humans. Second, these 
detrimental effects might be probably associated with long-term exposure to 5-HT, 
while we are hypothesing that short-term perioperative manipulation of IP 5-HT levels 
may be beneficial after hepatectomy. The therapeutic window to increase IP 5-HT may 
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be of crucial importance. Based on our data, the most reasonable approach of interfering 
with IP 5-HT levels to support liver regeneration would presumably be a short-term 
elevation prior to liver surgery as well as within the first postoperative week. This 
therapeutic setting will have to be evaluated with respect to potential deleterious effects 
on the underlying liver disease. In this context, Nozaki et al. documented that the 
controlled increase of platelets (and therefore presumably available 5-HT) using 
thrombopoietin, had no proliferative effect on hepatocellular carcinoma in vitro or in 
vivo.3 This finding supports the notion that a temporary, perioperative increase of 
platelet counts and concomitantly 5-HT, might have limited adverse effects on liver 
cancer. 
Most importantly, it should be stated that postoperative liver failure is frequently a fatal 
complication after liver resection.4 As specific therapeutic options to accelerate liver 
regeneration are missing to date, we would strongly argue for evaluating 5-HT as a 
therapeutic target. A careful definition of treatment indications and therapeutic timing 
may be key to promote liver regeneration without inducing potential deleterious effects. 
 
 
 
 
 
 
 
 
 
 
Page 2 of 3
Hepatology
Hepatology
References: 
1. Starlinger P, Assinger A, Haegele S, Wanek D, Zikeli S, Schauer D, et al. Evidence 
for serotonin as a relevant inducer of liver regeneration after liver resection in humans. 
Hepatology, Epub 2013. 
2. Lesurtel M, Soll C, Humar B, Clavien PA. Serotonin: a double-edged sword for the 
liver? Surgeon 2012;10:107-113. 
3. Nozaki R, Murata S, Nowatari T, Maruyama T, Ikeda N, Kawasaki T, et al. Effects of 
thrombopoietin on growth of hepatocellular carcinoma: Is thrombopoietin therapy for 
liver disease safe or not? Hepatol Res 2013;43:610-620. 
4. Balzan S, Belghiti J, Farges O, Ogata S, Sauvanet A, Delefosse D, et al. The "50-50 
criteria" on postoperative day 5: an accurate predictor of liver failure and death after 
hepatectomy. Ann Surg 2005;242:824-828, discussion 828-829. 
 
 
Page 3 of 3
Hepatology
Hepatology
